Steward Partners Investment Advisory LLC purchased a new stake in shares of Bausch Health Companies Inc (NYSE:BHC) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 4,130 shares of the company’s stock, valued at approximately $106,000.
A number of other hedge funds also recently made changes to their positions in BHC. Bank of Montreal Can acquired a new position in Bausch Health Companies during the third quarter valued at approximately $94,432,000. Private Management Group Inc. acquired a new position in Bausch Health Companies during the second quarter valued at approximately $28,474,000. Tobam acquired a new position in Bausch Health Companies during the second quarter valued at approximately $13,886,000. Van ECK Associates Corp acquired a new position in Bausch Health Companies during the second quarter valued at approximately $11,494,000. Finally, Andra AP fonden acquired a new position in Bausch Health Companies during the third quarter valued at approximately $7,039,000. Institutional investors own 43.28% of the company’s stock.
Several brokerages have commented on BHC. Zacks Investment Research upgraded Bausch Health Companies from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a report on Wednesday, October 3rd. ValuEngine downgraded shares of Bausch Health Companies from a “hold” rating to a “sell” rating in a research note on Tuesday, October 2nd. Mizuho restated a “buy” rating and issued a $35.00 price objective on shares of Bausch Health Companies in a research note on Monday, October 8th. Royal Bank of Canada set a $30.00 price objective on shares of Bausch Health Companies and gave the stock a “hold” rating in a research note on Monday, October 8th. Finally, HC Wainwright set a $25.00 price objective on shares of Bausch Health Companies and gave the stock a “hold” rating in a research note on Monday, October 8th. Three analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $26.89.
In other news, CFO Paul Herendeen bought 10,000 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 14th. The stock was purchased at an average cost of $22.61 per share, with a total value of $226,100.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christina Ackermann sold 19,946 shares of the firm’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total value of $498,251.08. The disclosure for this sale can be found here. In the last 90 days, insiders bought 165,000 shares of company stock worth $3,890,700. 11.54% of the stock is currently owned by corporate insiders.
Shares of Bausch Health Companies stock opened at $24.17 on Friday. The firm has a market capitalization of $8.00 billion, a PE ratio of 6.31, a P/E/G ratio of 0.33 and a beta of -0.27. The company has a debt-to-equity ratio of 6.99, a quick ratio of 0.89 and a current ratio of 1.14. Bausch Health Companies Inc has a 1 year low of $11.10 and a 1 year high of $28.45.
Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Tuesday, August 7th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.12. The business had revenue of $2.13 billion for the quarter, compared to the consensus estimate of $2.05 billion. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. On average, sell-side analysts anticipate that Bausch Health Companies Inc will post 3.46 earnings per share for the current year.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
See Also: How much money do you need to begin day trading?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.